Stephen Parey, MD
Otolaryngology · Columbia, TNNPI 1093753626
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,304 of the $4,073 with a category attached, or 81.1%. It is spread thinly across 34 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations.
Across 136 payments — averaging $29.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Verathon Inc.$550
- Inspire Medical Systems, Inc.$509
- GSK$424
- Aerin Medical Inc.$382
- Regeneron Healthcare Solutions, Inc.$318
- Stryker$247
- plus $2K from 28 others
What the payments were for
- Consulting fees$73518%
- Food & beverage$3,30481%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Verathon Inc. | 1 | $550 |
| Inspire Medical Systems, Inc. | 7 | $509 |
| GSK | 22 | $424 |
| Aerin Medical Inc. | 7 | $382 |
| Regeneron Healthcare Solutions, Inc. | 12 | $318 |
| Stryker | 12 | $247 |
| Jazz Pharmaceuticals Inc. | 12 | $237 |
| Medtronic | 5 | $171 |
| Sanofi | 6 | $154 |
| Microline Surgical Inc | 2 | $126 |
| Intersect ENT, Inc. | 7 | $96 |
| 3b Medical, Inc. | 4 | $79 |
| AstraZeneca | 5 | $76 |
| Acclarent, Inc | 2 | $69 |
| Alk-abello, Inc | 3 | $56 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $49 |
| Smith+Nephew | 2 | $47 |
| Harmony Biosciences LLC | 2 | $44 |
| Pfizer | 2 | $43 |
| AbbVie | 2 | $41 |
| Merck | 3 | $39 |
| Phadia US Inc. | 2 | $38 |
| Amgen | 1 | $34 |
| Novartis | 2 | $31 |
| Philips North America LLC | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Optinose US, Inc. | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,073 in reported general payments places this provider in the 80th percentile of 191 otolaryngology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 167 | $7,688 |
| Epinephrine | 25 | $5,251 |
| Azelastine Hcl | 157 | $4,594 |
| Fluocinolone Acetonide Oil | 76 | $2,931 |
| Montelukast Sodium | 230 | $2,827 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 25 | $2,736 |
| Fluticasone Propionate | 194 | $2,585 |
| Omeprazole | 253 | $2,247 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 22 | $1,847 |
| CefuroximeCefuroxime Axetil | 95 | $1,556 |
| Mometasone Furoate | 14 | $1,360 |
| Pantoprazole Sodium | 157 | $1,356 |
| Levocetirizine Dihydrochloride | 122 | $1,267 |
| Mupirocin | 46 | $1,012 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 70 | $898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $16 | $5,25125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 191 otolaryngology providers in Tennessee.
Other otolaryngology in Columbia
- Shaun CorbinColumbia$3K
- Rakesh ChandraNashville$381K
- David FortuneHermitage$298K
- Grady BryantHermitage$74K
- Marion GillespieMemphis$67K
- Clyde MathisonFarragut$66K
- Dean KlugGermantown$37K
- Michael TopfNashville$36K
- John GleysteenMemphis$25K
- Allan RosenbaumPowell$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.